CTNNA1: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: CTNNA1

NCBI ID: G1495

CTNNA1: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, affecting over 21,000 new cases every year in the United States alone. Despite advances in treatment, the survival rate for ovarian cancer remains low, with a five-year survival rate of only 29%. Therefore, there is a need for new treatments and better diagnostic tools to improve outcomes.

CTNNA1, also known as Catenin alpha-1 (isoform 1), is a protein that is expressed in various tissues, including the uterus, breast tissue, and brain. It has been shown to be involved in various cellular processes, including cell signaling, migration, and invasion. In recent years, researchers have become interested in using CTNNA1 as a potential drug target or biomarker for ovarian cancer.

CDKN2A, a gene that encodes the tumor suppressor protein p16INK4a, is a well-established gene that has been implicated in the development and progression of ovarian cancer. CDKN2A has been shown to be expressed in various types of ovarian cancer, including epithelial, endometrial, and fallopian tube cancers. In addition, high levels of CDKN2A have been associated with poor prognosis in ovarian cancer patients.

CTNNA1 has been shown to interact with CDKN2A, which could potentially lead to the regulation of CDKN2A expression and the development of ovarian cancer. Researchers have found that high levels of CTNNA1 were associated with poor prognosis in ovarian cancer patients, and that inhibition of CTNNA1 could increase the sensitivity of ovarian cancer cells to chemotherapy.

In addition to its potential as a drug target, CTNNA1 has also been shown to be a potential biomarker for ovarian cancer. The expression of CTNNA1 has been shown to be associated with the severity of ovarian cancer, as well as the response to chemotherapy. In addition, researchers have found that the levels of CTNNA1 have been associated with the expression of other genes that are involved in the development and progression of ovarian cancer.

The potential of CTNNA1 as a drug target or biomarker for ovarian cancer is an exciting area of research, with potential implications for the treatment of ovarian cancer. Further studies are needed to fully understand the role of CTNNA1 in ovarian cancer and to develop new diagnostic tools that can be used to identify ovarian cancer at an early stage.

In conclusion, CTNNA1 is a protein that has been shown to be involved in various cellular processes, including cell signaling and migration. In recent years, researchers have become interested in using CTNNA1 as a potential drug target or biomarker for ovarian cancer. Further studies are needed to fully understand its role in the development and progression of ovarian cancer and to develop new diagnostic tools that can be used to identify ovarian cancer at an early stage.

Protein Name: Catenin Alpha 1

Functions: Associates with the cytoplasmic domain of a variety of cadherins. The association of catenins to cadherins produces a complex which is linked to the actin filament network, and which seems to be of primary importance for cadherins cell-adhesion properties. Can associate with both E- and N-cadherins. Originally believed to be a stable component of E-cadherin/catenin adhesion complexes and to mediate the linkage of cadherins to the actin cytoskeleton at adherens junctions. In contrast, cortical actin was found to be much more dynamic than E-cadherin/catenin complexes and CTNNA1 was shown not to bind to F-actin when assembled in the complex suggesting a different linkage between actin and adherens junctions components. The homodimeric form may regulate actin filament assembly and inhibit actin branching by competing with the Arp2/3 complex for binding to actin filaments. Involved in the regulation of WWTR1/TAZ, YAP1 and TGFB1-dependent SMAD2 and SMAD3 nuclear accumulation (By similarity). May play a crucial role in cell differentiation

More Common Targets